Biotechnology company OSE Immunotherapeutics (Euronext Paris:OSE) announced on Tuesday the launch of the Artemia trial to evaluate its cancer vaccine, Tedopi, in second-line treatment for metastatic non-small cell lung cancer (NSCLC).
The trial is being conducted in multiple countries and regions, including the United States, Canada, Europe and the United Kingdom.
Tedopi is a neoepitope-based vaccine designed to stimulate the immune system to target cancer cells. The Artemia trial will compare Tedopi to standard of care in HLA-A2 positive patients with NSCLC who have progressed after treatment with immune checkpoint inhibitors. The primary endpoint of the trial is overall survival.
OSE believes that Tedopi has the potential to address a significant unmet medical need for patients with advanced NSCLC.
The study is intended to support the registration of Tedopi, in parallel with the companion diagnostic for HLA-A2 positive patients.
NSCLC accounts for 85% of all lung cancers and the HLA-A2 phenotype represents about 45% of the population.
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Sanofi in talks to sell Opella stake
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
Anixa Biosciences plans Phase 2 breast cancer vaccine study
MedImmune's FluMist nasal spray influenza vaccine receives US FDA approval
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine